1. Klevens RM, Edwards JR, Richards CL Jr, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 2007; 122:160-6.
2. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-39.
3. Vincent JL. Nosocomial infections in adult intensive-care units. Lancet 2003; 361:2068-77.
4. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006 Dec 28; 355(26):2725-32.
5. Scott RD. The direct medical costs of healthcare-associated infections in U.S. hospitals and the benefits of prevention. (PDF File, 835 KB). Accessed August 7, 2013.
6. Pennsylvania Health Care Cost Containment Council (PHC4). The impact of healthcare-associated infections in Pennsylvania, 2010. 2012. . Accessed August 7, 2013.
7. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by MRSA, United States, 1999-2005. Emerg Infect Dis 2007; 13(12):1840-6.
8. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298(15):1763-71.
9. Jarvis WR, Scholosser J, Chinn RY, et al. National prevalence of methicillin-resistant Staphylococcus aureus in inpatients at U.S. health care facilities, 2006. Am J Infect Control 2007; 35(10):631-7.
10. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013 Jan; 34(1):1-14.
11. Umscheid CA, Mitchell MD, Doshi JA, et al. Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. Infect Control Hosp Epidemiol 2011; 32(2):101-14.
12. Hidron AI, Kourbatova EV, Halvosa JS, et al. Risk factors for colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban hospital: emergence of community-associated MRSA nasal carriage. Clin Infect Dis 2005; 41:159-66.
13. Perlin JB, Hickok JD, Septimus EJ, et al. A bundled approach to reduce methicillin-resistant Staphylococcus aureus infections in a system of community hospitals. J Healthc Qual 2013; 35:57-68.
14. Huang SS, Rifas-Shiman SL, Warren DK, et al. Improving methicillin-resistant Staphylococcus aureus surveillance and reporting in intensive care units. J Infect Dis 2007; 195(3):330-8.
15. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009 Dec 2; 302(21):2323-9.
16. Huang SS, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis 2003; 36(3):281-5.
17. Datta R, Huang SS. Risk of infection and death due to Methicillin-resistant Staphylococcus aureus in long-term carriers. Clin Infect Dis 2008; 47(2):176-81.
18. Huang SS, Hinrichsen VL, Datta R, et al. Methicillin-resistant Staphylococcus aureus infection and hospitalization in high-risk patients in the year following detection. PLoS ONE 2011; 6(9):e24340.
19. Vernon MO, Hayden MK, Trick WE, et al. Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. Arch Intern Med 2006 Feb 13; 166(3):306-12.
20. Bleasdale SC, Trick WE, Gonzalez IM, et al. Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med 2007 Oct 22; 167(19):2073-9.
21. Popovich KJ, Hota B, Hayes R, et al. Effectiveness of routine patient cleansing with chlorhexidine gluconate for infection prevention in the medical intensive care unit. Infect Control Hosp Epidemiol 2009 Oct; 30(10):959-63.
22. Climo MW, Sepkowitz KA, Zuccotti G, et al. The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and healthcare-associated bloodstream infections: results of a quasi-experimental multicenter trial. Crit Care Med 2009 Jun; 37(6):1858-65.
23. Huang SS, Septimus E, Kleinman K, et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med 2013 Jun 13; 368 (24):2255-65.
24. Casewell MW, Hill RL. Elimination of nasal carriage of Staphylococcus aureus with mupirocin ("pseudomonic acid"): a controlled trial. J Antimicrob Chemother 1986; 17:365–72.
25. Doebbeling BN, Reagan DR, Pfaller MA, et al. Long-term efficacy of intranasal mupirocin ointment: a prospective cohort study of Staphylococcus aureus carriage. Arch Intern Med 1994; 154:1505–8.
26. Fernandez C, Gaspar C, Torrellas A, et al. A double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of Staphylococcus aureus among hospital personnel. J Antimicrob Chemother 1995; 35:399–408.
27. Ammerlaan HSM, Kluytmans JAJW, Wertheim HFL, et al. Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis 2009; 48:922-30.
28. Ridenour G, Lampen R, Fiderspiel J, et al. Use of intranasal mupirocin and chlorhexidine bathing and the incidence of methicillin-resistant Staphylococcus aureus colonization and infection among intensive care units patients. Infect Control Hosp Epidmiol 2007; 28:1155-61.
29. Girou E, Pujade G, Legrand P, et al. Selective screening of carriers for control of methicillin-resistant Staphylococcus aureus (MRSA) in high-risk hospital areas with a high level of endemic MRSA. Clin Infect Dis 1998; 27:543-50.
30. Sandri AM, Dalarosa MG, Ruschel de AL, et al. Reduction in incidence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive care unit: role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA. Infect Control Hosp Epidemiol 2006; 27:185-87.
31. Harbarth S, Dharan S, Liassine N, et al. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43:1412-6.
32. Basker M J, Comber KR, Clayton P J, et al. Ethyl monate A: a semisynthetic antibiotic derived from pseudomonie acid A. In: Nelson JD, Grassi C, eds. Current chemotherapy and infectious disease vol. 1. Washington, DC: American Society for Microbiology; 1980. p. 471-3.
33. Jackson D, Tasker TOG, Suthefland K, et a Clinical pharmacology of Bactroban: pharmaeokinetic, tolerance and efficacy studies. Proceedings of an International Symposium Bactroban (Mupirocin), Nassau, May 1984. Excerpts Meal Curr Clin Pract Ser 1985; 16:54-67.
34. Baines PJ, Jackson D, Mellows G, et al. Mupirocin: Its chemistry and metabolism. In: Wilkinson JD, Price JD, eds. Mupirocin—A novel topical antibiotic. London: Royal Society of Medicine, 1984: 13-22.
35. Bork K, Brauers J, Kresken M. Efficacy and safety of 2% mupirocin ointment in the treatment of primary and secondary skin infections–an open multicentre trial. Br J Clin Pract 1989 Aug; 43(8):284-8.
36. Lawrence CM, Mackenzie T, Pagano K, et al. Systemic absorption of mupirocin after topical application of mupirocin ointment to healthy and dermatologically diseased skin. J Dermatolog Treat 1989;(I):83-86.
37. Pappa KA. The clinical development of mupirocin. J Am Acad Dermatol 1990; 22(5pt1):873-9.
38. Gilbert M. Topical 2% mupirocin versus 2% fusidic acid ointment in the treatment of primary and secondary skin infections. J Am Acad Dermatol 1989; 20:1083-87.
39. Garibaldi RA. Prevention of intra-operative wound contamination with chlorhexidine shower and scrub. J Hosp Infect 1988; 11(SupplB) 5-9.
40. Paulson DS. Efficacy evaluation of a 4% chlorhexidine gluconate as a full-body shower wash. Am J Infect Control 1993; 21(4):205-9.
41. Hayek IJ, Emerson JM, Gardner AM. Placebo-controlled trial of the effect of two preoperative baths or showers with chlorhexidine detergent on postoperative wound infection rates. J Hosp Infect 1987; 10:165-72.
42. Leigh DA, Stronge JL, Marriner J, et al. Total body bathing with 'Hibiscrub'(chlorhexidine) in surgical patients: a controlled trial. J Hosp Infect 1983; 4:229-35.
43. Ayliffe GA, Noy MF, Babb JR, et al. A comparison of pre-operative bathing with chlorhexidine-detergent and non-medicated soap in the prevention of wound infection. J Hosp Infect 1983; 4:237-44.
44. Gould IM, MacKenzie FM, MacLennan G, et al. Topical antimicrobials in combination with admission screening and barrier precautions to control endemic methicillin-resistant Staphylococcus aureus in an intensive care unit. Int J Antimicrob Agents 2007; 29(5):536-43.
45. McEvoy GK (ed.). American hospital formulary service-drug information, 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc; 2003 (plus supplements), p. 2621.
46. Soskolne WA, Chajek T, Flashner M, et al. An in vivo study of the chlorhexidine release profile of the PerioChip in the gingival crevicular fluid, plasma and urine. J Clin Periodontol 1998; 25(12):1017-21.
47. Ibanez N, Casamada N. Chlorhexidine: the ideal antiseptic. Rev Enferm 2005; 28(9):31-5.
48. Lim KS, Kam PC. Chlorhexidine— pharmacology and clinical application. Anaesth Intensive Care 2008; 36(4):502-12.
49. Climo MW, Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 2013 Feb 7; 368(6):533-42.
50. Milstone AM, Elward A, Song X, et al. Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial. Lancet 2013 Mar; 381(9872):1099-106.
